FDA Panel To Weigh REMS For Jazz's Fibromyalgia Candidate
This article was originally published in The Pink Sheet Daily
Discussions on sodium oxybate likely to stray into effectiveness of current risk management measures for company's narcolepsy drug Xyrem, which contains the same active ingredient.
You may also be interested in...
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.